News

MM-141 is a tetravalent bispecific antibody that blocks tumor survival signals by targeting receptor complexes containing IGF-1R and ErbB3 (HER3), which activate a major cellular signaling pathway that

DRP, which is a highly validated systems-biology-based biomarker platform, has been developed by MPI and it is useful for identifying likely responding patients for targeted enrollment of cancer

The trial is designed to assess ThermoDox in combination with radiofrequency ablation standardized to 45 minutes (sRFA) versus sRFA alone to treat patients with non-resectable HCC lesions. ThermoDox

The MMRF, in collaboration with the U.S. Food and Drug Administration (FDA), the National Cancer Institute (NCI), pharmaceutical, biotech and diagnostic industry members, academic center leaders and patients,

Under the terms of the agreement, Invetech will provide Argos with services, technology and equipment to support the design, development, supply and maintenance of customized manufacturing systems to

CARBAVANCEis a combination of the carbapenem antibiotic, meropenem, combined with RPX7009, the first of a novel class of beta-lactamase inhibitors. Beta-lactamase inhibitors are agents that inhibit bacterial enzymes,

BL-7010 was found to be safe and well tolerated in both single- and repeated-dose administrations, and the optimal safe dose for future development was determined. Over the next

Mepolizumab is delivered in a 100mg dose via subcutaneous injection every four weeks. Eosinophilic asthma is identified by a blood eosinophil count of at least 150 cells per

ADXS31-142 is the company’s lead Lm-LLO immunotherapy designed to specifically target prostate-specific antigen (PSA). Following FDA’s acceptance of the IND submission, the proposed Phase I/II protocol will assess